Berberine attenuates cAMP-induced lipolysis via reducing the inhibition of phosphodiesterase in 3T3-L1 adipocytes

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1812, Issue 4, 2011, Pages 527-535

  Zhou, Libin ^a   Wang, Xiao ^a   Yang, Ying ^a   Wu, Ling ^a   Li, Fengying ^a   Zhang, Rong ^a   Yuan, Guoyue ^a   Wang, Ning ^a   Chen, Mingdao ^a   Ning, Guang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Adipocytes; AMPK; Berberine; CAMP signaling; Lipolysis; Phosphodiesterase

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; BERBERINE; CATECHOLAMINE; CYCLIC AMP; FORSKOLIN; HORMONE SENSITIVE LIPASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; ISOBUTYLMETHYLXANTHINE; ISOPRENALINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PERILIPIN; PHOSPHODIESTERASE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IIIB; PHOSPHODIESTERASE IV; RNA; SERINE DERIVATIVE; UNCLASSIFIED DRUG; WORTMANNIN;

ADIPOCYTE; ARTICLE; ATTENUATION; CELL DIFFERENTIATION; CELL STRAIN 3T3; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; HYDROLYSIS; LIPOLYSIS; LIPOLYSIS INHIBITION; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; WESTERN BLOTTING;

1-METHYL-3-ISOBUTYLXANTHINE; 3T3-L1 CELLS; ADIPOCYTES; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BERBERINE; CATECHOLAMINES; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; FORSKOLIN; HYPOGLYCEMIC AGENTS; LIPOLYSIS; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHODIESTERASE INHIBITORS; PHOSPHOPROTEINS; STEROL ESTERASE;

RATTUS;

EID: 79951680770     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.10.001     Document Type: Article

References (40)

1. Bergman R.N., Finegood D.T., Kahn S.E. The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes. Eur. J. Clin. Invest. 2002, 32(Suppl 3):35-45.
2. Boden G. Free fatty acids, insulin resistance and type 2 diabetes mellitus. Proc. Ass. Am. Physicians 1999, 111:241-248.
3. Frayn K.N. Adipose tissue as a buffer for daily lipid flux. Diabetologia 2002, 45:259-265.
4. Unger R.H. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: genetic and clinical implications. Diabetes 1995, 44:863-870.
5. Kim J.K., Fillmore J.J., Chen Y., Yu C., Moore I.K., Pypaert M., Lutz E.P., Kako Y., Velez-Carrasco W., Goldberg I.J., Breslow J.L., Shulman G.I. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:7522-7527.
6. Shimabukuro M., Zhou Y.T., Levi M., Unger R.H. Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc. Natl Acad. Sci. USA 1998, 95:2498-24502.
7. Claus T.H., Lowe D.B., Liang Y., Salhanick A.I., Lubeski C.K., Yang L., Lemoine L., Zhu J., Clairmont K.B. Specific inhibition of hormone-sensitive lipase improves lipid profile while reducing plasma glucose. J. Pharmacol. Exp. Ther. 2005, 315:1396-1402.
8. Holm C. Molecular mechanisms regulating hormone-sensitive lipase and lipolysis. Biochem. Soc. Trans. 2003, 31:1120-1124.
9. Clifford G.M., Londos C., Kraemer F.B., Vernon R.G., Yeaman S.J. Translocation of hormone-sensitive lipase and perilipin upon lipolytic stimulation of rat adipocytes. J. Biol. Chem. 2000, 275:5011-5015.
10. Botion L.B., Green A. Long-term regulation of lipolysis and hormone-sensitive lipase by insulin and glucose. Diabetes 1999, 48:1691-1697.
11. Chen Q.M., Xie M.Z. Studies on the hypoglycemic effect of Coptis chinensis and berberine. Yao Xue Xue Bao 1986, 21:401-406.
12. Zhang Y., Li X., Zou D., Liu W., Yang J., Zhu N., Huo L., Wang M., Hong J., Wu P., Ren G., Ning G. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J. Clin. Endocrinol. Metab. 2008, 93:2559-2565.
13. Lee Y.S., Kim W.S., Kim K.H., Yoon M.J., Cho H.J., Shen Y., Ye J.M., Lee C.H., Oh W.K., Kim C.T., Hohnen-Behrens C., Gosby A., Kraegen E.W., James D.E., Kim J.B. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 2006, 55:2256-2264.
14. Turner N., Li J.Y., Gosby A., To S.W., Cheng Z., Miyoshi H., Taketo M.M., Cooney G.J., Kraegen E.W., James D.E., Hu L.H., Li J., Ye J.M. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes 2008, 57:1414-1418.
15. Kong W., Wei J., Abidi P., Lin M., Inaba S., Li C., Wang Y., Wang Z., Si S., Pan H., Wang S., Wu J., Wang Y., Li Z., Liu J., Jiang J.D. Berberine is a novel cholesterol lowering drug working through a unique mechanism distinct from statins. Nat. Med. 2004, 10:1344-1351.
16. Zhou L., Wang X., Shao L., Yang Y., Shang W., Yuan G., Jiang B., Li F., Tang J., Jing H., Chen M. Berberine acutely inhibits insulin secretion from beta cells through cAMP signaling pathway. Endocrinology 2008, 149:4510-4518.
17. Leng S.H., Lu F.E., Xu L.J. Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion. Acta Pharmacol. Sin. 2004, 25:496-502.
18. Reed B.C., Lane M.D. Insulin receptor synthesis and turnover in differentiating 3T3-L1 preadipocytes. Proc. Natl Acad. Sci. USA 1980, 77:285-289.
19. Green A., Rumberger J.M., Stuart C.A., Ruhoff M.S. Stimulation of lipolysis by tumor necrosis factor-alpha in 3T3-L1 adipocytes is glucose dependent: implications for long-term regulation of lipolysis. Diabetes 2004, 53:74-81.
20. Zhang W., Ke H., Tretiakova A.P., Jameson B., Colman R.W. Identification of overlapping but distinct cAMP and cGMP interaction sites with cyclic nucleotide phosphodiesterase 3A by site-directed mutagenesis and molecular modeling based on crystalline PDE4B. Protein Sci. 2001, 10:1481-1489.
21. Greenberg A.S., Shen W.J., Muliro K., Patel S., Souza S.C., Roth R.A., Kraemer F.B. Stimulation of lipolysis and hormone-sensitive lipase via the extracellular signal-regulated kinase pathway. J. Biol. Chem. 2001, 276:45456-45461.
22. Li J., Elberg G., Sekar N., He Z.B., Shechter Y. Antilipolytic actions of vanadate and insulin in rat adipocytes mediated by distinctly different mechanisms. Endocrinology 1997, 138:2274-2279.
23. Zhou L., Yang Y., Wang X., Liu S., Shang W., Yuan G., Li F., Tang J., Chen M., Chen J. Berberine stimulates glucose transport through a mechanism distinct from insulin. Metabolism 2007, 56:405-412.
24. Okada T., Kawano Y., Sakakibara T., Hazekai O., Ui M. Essential role of phosphatidylinositol 3-kinase in insulin-induced glucose transport and antilipolysis in rat adipocytes. J. Biol. Chem. 1994, 269:3568-3573.
25. Daval M., Diot-Dupuy F., Bazin R., Hainault I., Viollet B., Vaulont S., Hajduch E., Ferre P., Foufelle F. Anti-lipolytic action of AMP-activated protein kinase in rodent adipocytes. J. Biol. Chem. 2005, 280:25250-25257.
26. Brusq J.M., Ancellin N., Grondin P., Guillard R., Martin S., Saintillan Y., Issandou M. Inhibition of lipid synthesis through activation of AMP-kinase: an additional mechanism for the hypolipidemic effects of berberine. J. Lipid Res. 2006, 47:1281-1288.
27. Yin W., Mu J., Birnbaum M.J. Role of AMP-activated protein kinase in cyclic AMP-dependent lipolysis In 3T3-L1 adipocytes. J. Biol. Chem. 2003, 278:43074-43080.
28. Garton A.J., Campbell D.G., Carling D., Hardie D.G., Colbran R.J., Yeaman S.J. Phosphorylation of bovine hormone-sensitive lipase by the AMP-activated protein kinase. A possible antilipolytic mechanism. Eur. J. Biochem. 1989, 179:249-254.
29. Groop L.C., Bonadonna R.C., DelPrato S., Ratheiser K., Zyck K., Ferrannini E., DeFronzo R.A. Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J. Clin. Invest. 1989, 84:205-213.
30. Shakur Y., Holst L.S., Landstrom T.R., Movsesian M., Degerman E., Manganiello V. Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family. Prog. Nucleic Acid Res. Mol. Biol. 2001, 66:241-277.
31. Xue B.Z., Greenberg A.G., Kraemer F.B., Zemel M.B. Mechanism of intracellular calcium ([Ca2+]i) inhibition of lipolysis in human adipocytes. FASEB J. 2001, 15:2527-2529.
32. Snyder P.B., Esselstyn J.M., Loughney K., Wolda S.L., Florio V.A. The role of cyclic nucleotide phosphodiesterases in the regulation of adipocyte lipolysis. J. Lipid Res. 2005, 46:494-503.
33. Sztalryd C., Kraemer F.B. Regulation of hormone-sensitive lipase in streptozotocin-induced diabetic rats. Metabolism 1995, 44:1391-1396.
34. Anthonsen M.W., Ronstrand L., Wernstedt C., Degerman E., Holm C. Identification of novel phosphorylation sites in hormone-sensitive lipase that are phosphorylated in response to isoproterenol and govern activation properties in vitro. J. Biol. Chem. 1998, 273:215-221.
35. Gauthier M.S., Miyoshi H., Souza S.C., Cacicedo J.M., Saha A.K., Greenberg A.S., Ruderman N.B. AMP-activated protein kinase is activated as a consequence of lipolysis in the adipocyte: potential mechanism and physiological relevance. J. Biol. Chem. 2008, 283:16514-16524.
36. Omar B., Zmuda-Trzebiatowska E., Manganiello V., Göransson O., Degerman E. Regulation of AMP-activated protein kinase by cAMP in adipocytes: roles for phosphodiesterases, protein kinase B, protein kinase A, Epac and lipolysis. Cell. Signal. 2009, 21:760-766.
37. Wang X., Zhou L., Li G., Luo T., Gu Y., Qian L., Fu X., Li F., Li J., Luo M. Palmitate activates AMP-activated protein kinase and regulates insulin secretion from beta cells. Biochem. Biophys. Res. Commun. 2007, 352:463-468.
38. Carmen G.Y., Víctor S.M. Signalling mechanisms regulating lipolysis. Cell. Signal. 2006, 18:401-408.
39. Vossler M.R., Yao H., York R.D., Pan M.G., Rim C.S., Stork P.J. cAMP activates MAP kinase and Elk-1 through a B-Raf- and Rap1-dependent pathway. Cell 1997, 89:73-82.
40. Barge R.M., Falkenburg J.H., Willemze R., Maassen J.A. 8-Bromo-cAMP induces a proliferative response in an IL-3 dependent leukemic cell line and activates Erk 1, 2 via a Shc-independent pathway. Biochim. Biophys. Acta 1997, 1355:141-146.